RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride
In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder Marketbeat. It has even explored herbal COVID-19 remedies in the past, though these remain experimental Stocktitan. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding (largely from its founder) and IPO proceeds. In the